Repligen Corporation (RGEN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

251.35

+4.86

(+1.97%)

At close: 04:00PM EDT

250.03

-1.32

(-0.53%)

After hours:

06:36PM EDT

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bullishpattern detected

Price Crosses Moving Average

View all chart patterns

Performance Outlook

Previous Close	246.49
Open	248.00
Bid	120.00 x 800
Ask	300.00 x 900
Day's Range	243.08 - 251.62
52 Week Range	137.21 - 327.32
Volume	451,645
Avg. Volume	536,985

Market Cap	13.948B
Beta (5Y Monthly)	1.06
PE Ratio (TTM)	94.49
EPS (TTM)	2.66
Earnings Date	Oct 26, 2022 - Oct 31, 2022
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	266.56

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Near Fair Value

28% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for RGEN

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

Repligen Corporation
RGEN: Raising target price to $173.00REPLIGEN CORP has an Investment Rating of HOLD; a target price of $173.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of Medium.
Rating
Fair Value
Economic Moat
2 months agoArgus Research

All

Simply Wall St.
Repligen's (NASDAQ:RGEN) investors will be pleased with their incredible 525% return over the last five years
Buying shares in the best businesses can build meaningful wealth for you and your family. And we've seen some truly...
- The past five years for Pulse Seismic (TSE:PSD) investors has not been profitable
  Simply Wall St.
- Those who invested in Ariadne Australia (ASX:ARA) a year ago are up 34%
  Simply Wall St.
Benzinga
Catalent-Repligen Merger 'Seems Unlikely,' This Analyst Says
Yesterday, Catalent Inc (NYSE: CTLT) announced to acquire Metrics Contract Services for $475 million. Keybanc notes that the deal strengthens CTLT's oral delivery portfolio and targets rapidly growing biologic applications. Metrics produces highly active pharmaceutical ingredients that are very difficult to produce but very potent in small doses. "After recent acquisitions and capacity expansion on the cell and gene therapy front, this acquisition will continue to balance CTLT's portfolio, addin
Motley Fool
Why Shares of Repligen Surged This Week
The bioprocessing equipment company is seeing growth prospects accelerate for its non-COVID-related revenue.